Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

Inclusion Criteria: * Patients must have histologically confirmed metastatic uveal melanoma with measurable disease not eligible for curative therapy. * Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. Patients must have at least 1 biopsiable liver metastasis. * Patients can have received one prior therapy for metastatic disease, excepting for treatments listed in exclusion criteria. * Patients must be 18 years of age or older at time of study entry. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. * Adequate normal organ and marrow function as defined below: Haemoglobin ≥9.0 g/dL, Absolute neutrophil count (ANC) \> 1.5 x 109/L (\> 1500 per mm3), Platelet count ≥ 100 x 109/L (\>100,000 per mm3). Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with Coordinating In…